Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reldesemtiv in COPD
NCT02662582Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of reldesemtiv in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Change From Period Baseline in Constant Work Rate Endurance Time at 2 weeks. Started Jun 2016; status: completed.
02
Drugs
reldesemtiv
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02662582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02662582.